Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

STABLE-MATES : A Randomised Phase III study of sub-lobar resection (SR) versus Stereotactic Ablative Radiotherapy (SABR) in high risk patients with Stage I Non-Small cell Lung Cancer

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

ThreePhase Three

18-99Age 18-99

Lung<br/>CancersCancer LocationLung

Multiple treatment types,Radiotherapy,Surgical | LungLung,Non-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase III trial is comparing surgery and radiation therapy in the treatment of stage I Non-Small Cell (NSC) Lung Cancer.

This trial is treating patients with Non-Small Cell (NSC) Lung Cancer.

This is a radiotherapy and surgical trial.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomised Phase III study of sub-lobar resection (SR) versus Stereotactic Ablative Radiotherapy (SABR) in high risk patients with Stage I Non-Small cell Lung Cancer

Cooperative Group

Joint Lung Cancer Trialist's Coalition (JoLT-Ca)

Other Non-Commercial Sponsor

University of Texas Southwestern Medical Center


Stereotactic Ablative Radiotherapy has been shown in single institution phase II and matched cohort studies to be effective at controlling primary early lung cancer. Recent pooled analysis of both the STARS and ROSEL randomized trials comparing SABR versus lobectomy have shown a significantly improved 3-year survival with SABR, giving further impetus for successful completion of a randomized trial . Pre-randomized trial- Patients will be screened and pre-randomized to either SR or SAbR. Informed consent will be obtained after patients are made aware of the randomized assignment. Despite pre-randomization prior to consent, patients maintain their right to accept or decline any/all study activities. Only consenting patients will be allowed to participate in study activities, including observation after either randomized treatments or observation after standard of care treatment, while those declining consent will be managed by their physician(s) off study.Patients will be accrued and followed for a minimum of 2-years after treatment.

Recruiting Hospitals Read MoreRead more

St Vincent's Hospital, Surgical Oncology (Cardiothoracics)
Ms Jane Mack
03 9231 4615

Peter MacCallum Cancer Centre
Ms Lisa Selbie
(03) 8559 7388

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.